Completed PHASE2 INTERVENTIONAL 2-arm NCT04993677

A Study of SEA-CD40 Given With Other Drugs in Cancers

An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies

Sponsor: Merck Sharp & Dohme LLC

Conditions Carcinoma, Non-Small- Cell Lung Melanoma

Interventions SEA-CD40 carboplatin pembrolizumab (KEYTRUDA®) pemetrexed

Updated 23 times since 2021 Last updated: Apr 23, 2025 Started: Oct 6, 2021 Primary completion: Jan 3, 2024 Completion: Nov 25, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Carcinoma, Non-Small- Cell Lung and Melanoma and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 23 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

23 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Jun 2025 — Sep 2025 [monthly]

Completed PHASE2
Apr 2025 — Jun 2025 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE2

▶ Show 18 earlier versions

Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Active Not Recruiting PHASE2
Apr 2023 — Feb 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Mar 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Apr 2022 — May 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Apr 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Sep 2021 — Oct 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Seagen Inc.

Data source: Seagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Athens, United States , Baton Rouge, United States , Canton, United States , Chicago, United States , Cleveland, United States , Dallas, United States , Durham, United States , Fort Myers, United States , Heidelberg, Germany , Houston, United States and 17 more locations